Fairmount Funds Management LLC - Jun 23, 2025 Form 4 Insider Report for GLYCOMIMETICS INC (CBIO)

Role: Director, 10%+ Owner
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol: CBIO
Transactions as of: Jun 23, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/23/2025, 06:48 PM
Previous filing: Jun 20, 2025
Next filing: Jul 14, 2025
SEC: View on sec.gov

Reporting Owners (4)

Name	Relationship	Address	Signature	Signature date	CIK
Fairmount Funds Management LLC	Director, 10%+ Owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN	/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC	2025-06-23	0001802528
Fairmount Healthcare Fund II L.P.	Director, 10%+ Owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN	/s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.	2025-06-23	0001769651
Kiselak Tomas	Director, 10%+ Owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN	/s/ Tomas Kiselak	2025-06-23	0001830177
Harwin Peter Evan	Director, 10%+ Owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN	/s/ Peter Harwin	2025-06-23	0001663607

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CBIO	Stock Option (Right to Buy)	Award	$0	+9.02K		$0.00	9.02K	Jun 23, 2025	Ordinary Shares	9.02K	$15.30	By: Peter Harwin	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase 9,023 of the Issuer's ordinary shares, which vest in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.
F2	Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying ordinary shares. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Content

This option represents a right to purchase 9,023 of the Issuer's ordinary shares, which vest in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying ordinary shares. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Remarks:

Fairmount and Fairmount Healthcare Fund II LP may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.